A Phase II, Randomised, Open-Label, Pilot Study to Evaluate the Safety and Effects on Bone Resorption of AZD0530 in Patients With Prostate Cancer or Breast Cancer With Metastatic Bone Disease. [Ensayo piloto, fase II, abierto y aleatorizado para evaluar la seguridad y los efectos de AZD0530 sobre la resorcion osea en pacientes con cancer de prostata o de mama con metastasis oseas]

Trial Profile

A Phase II, Randomised, Open-Label, Pilot Study to Evaluate the Safety and Effects on Bone Resorption of AZD0530 in Patients With Prostate Cancer or Breast Cancer With Metastatic Bone Disease. [Ensayo piloto, fase II, abierto y aleatorizado para evaluar la seguridad y los efectos de AZD0530 sobre la resorcion osea en pacientes con cancer de prostata o de mama con metastasis oseas]

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2016

At a glance

  • Drugs Saracatinib (Primary) ; Zoledronic acid
  • Indications Breast cancer; Cancer metastases; Prostate cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Jan 2012 Planned end date changed from 1 Sep 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 27 May 2011 Planned end date changed from 1 Jul 2010 to 1 Sep 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top